据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最长 可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 | 代码 | 名称 | 张唱 | 总金额 | 总市值 | 现价 | | --- | --- | --- | --- | --- | --- | | 300463 | 迈克生物 | +20.03% | 7666.6 | 85.86 Z | 14.20 | | 300638 | 凯普生物 | +20.03% | 3.36 Z | 46.87 G | 7.25 | | 688317 | 之江生物 | +20.01% | 3.20 乙 | 49.10 Z | 25.55 | | 301207 | 华兰疫苗 | +20.00% | 5.75 G | 140.3 Z | 23.34 | | 688670 | 金 ...

据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 据央视新闻，近期，印度东部的西孟加拉邦出现尼帕病毒感染病例，目前已有5例确诊病例，其中包括 医护人员。据悉，近100人被要求居家隔离，感染者正在该邦首府加尔各答及周边医院接受治疗，其中 一名患者病情危重。 据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最 长可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 1月26日，流感板块午后拉升，截至发稿，迈克生物、凯普生物、之江生物、华兰疫苗20%涨停，达 安基因、特一药业、鲁抗医药、科华生物等涨停，智飞生物、万孚生物、康希诺、沃森生物等涨超 10%。 ...

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

证券之星消息，1月23日生物制品板块较上一交易日上涨1.45%，沃森生物领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收于14439.66，上涨0.79%。生物制品板块个股涨跌见下表： 从资金流向上来看，当日生物制品板块主力资金净流入1.98亿元，游资资金净流出2.72亿元，散户资金净 流入7437.55万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300142 沃森生物 | | 1.34 Z | 9.80% | -8331.39万 | -6.11% | -5032.70万 | -3.69% | | 000661 | 长春高新 | 5154.65万 | 8.00% | -1654.92万 | -2.57% | -3499.73万 | -5.43% | | 002252 上海莱士 | | 4593.03万 | 13.12% | -2426.69万 | - ...

证券代码：300142 证券简称：沃森生物 公告编号：2026-008 云南沃森生物技术股份有限公司 关于召开2026年第一次临时股东会的提示性公告 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 1 月 27 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为 2026 年 1 月 27 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 1 月 20 日 7、出席对象： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 经云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会第三 十五次会议审议通过，决定于 2026 年 1 月 27 日（星期二）召开公司 2026 年第一 次临时股东会。本次股东会的会议通知已于 2026 年 1 月 9 日公布于中国证监会指 定的创业板信息披露网站巨潮资讯网。本次股东会将采用现场会议与网络投票相 结合的方式召开。现就本次股东会的相关事宜再次 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

Core Viewpoint - Watson Bio's stock has shown fluctuations in price and trading volume, with a notable increase in share price since the beginning of the year, despite recent declines in the short term [1]. Financial Performance - For the period from January to September 2025, Watson Bio reported a revenue of 1.719 billion yuan, representing a year-on-year decrease of 19.73% [2]. - The net profit attributable to shareholders for the same period was 163 million yuan, down 36.24% year-on-year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Watson Bio was 114,000, a decrease of 2.75% from the previous period [2]. - The average number of circulating shares per shareholder increased by 2.83% to 13,643 shares [2]. Dividend Distribution - Since its A-share listing, Watson Bio has distributed a total of 451 million yuan in dividends, with 95.96 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, the largest circulating shareholder was E Fund's ChiNext ETF, holding 34.4714 million shares, a decrease of 5.8005 million shares from the previous period [3]. - Other notable institutional shareholders include Southern CSI 500 ETF and China Merchants National Bio-Medical Index A, both of which also saw reductions in their holdings [3].

Core Viewpoint - Watson Bio emphasizes its commitment to shareholder returns through consistent cash dividends, adhering to regulations and company bylaws [1] Group 1: Dividend Policy - The company has maintained a stable and transparent dividend policy, having issued annual cash dividends for five consecutive years since 2020 [1] - Future profit distribution plans will be developed in compliance with relevant regulations and the company's bylaws, considering various factors [1] - The company strictly follows the guidelines for cash dividends as outlined in the regulatory documents [1]

Core Viewpoint - Watson Bio emphasizes the importance of biomanufacturing as a national strategic emerging industry, highlighting its economic, social, and environmental benefits for sustainable development [1] Group 1: Company Mission and Strategy - The company adheres to the mission of "sowing health and creating beauty," aiming for "everyone to be born healthy" [1] - It actively responds to technological innovations and changes in the industry environment by integrating production, education, research, and application [1] - The company is focused on enhancing its technological innovation capabilities while leveraging existing industrial advantages [1] Group 2: Product Development and Pipeline - In addition to its existing human vaccine business, the company is expanding its product pipeline in biomanufacturing, which includes nutrients, natural active ingredients, and functional proteins [1] - The company is systematically advancing research and industrialization of these new product categories [1] - Further product details will be disclosed in future company communications [1]

Group 1 - The company, Watson Bio (300142), is closely monitoring the application of new technologies in vaccine product research and manufacturing [1] - The company advises investors to refer to its disclosed announcements for information regarding its research and technological reserves [1]